Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2008

01-12-2008 | Research Article

Consumer satisfaction with opioid treatment services at community pharmacies in Australia

Authors: Toby Lea, Janie Sheridan, Adam Winstock

Published in: International Journal of Clinical Pharmacy | Issue 6/2008

Login to get access

Abstract

Objective To explore consumer satisfaction with, and experiences of, a range of issues associated with the delivery of opioid substitution treatment at community pharmacies in New South Wales, Australia. Setting 50 community pharmacies providing opioid substitution treatment in New South Wales. Method Self-completion survey completed by 508 clients during supervised dosing. Main outcome measure Satisfaction with opioid substitution treatment delivery at community pharmacies. Results Sixty-one percent of participants reported being satisfied with their treatment programme. Participants expressed a high level of satisfaction with most aspects of opioid substitution treatment delivery at their pharmacy (aggregate mean = 8.1/10; 10 = excellent). However, participants were less satisfied with the level of privacy afforded at the pharmacy. Thirty-four percent reported that they were made to wait longer than other customers, and 25% reported that the pharmacy staff did not treat them the same as other customers. However, 87% reported that they felt welcomed by the pharmacy staff. Twenty-three percent of clients were currently in debt to the pharmacy for nonpayment of dispensing fees. The mean amount of current debt was $71.75, equivalent to approximately 2 weeks of pharmacy dispensing fees. Conclusion Community pharmacies providing opioid substitution treatment in New South Wales appear to be providing a level of service that is satisfactory to the clients of those services. However, many participants were concerned about a lack of privacy, the high cost of treatment, and being treated differently to other customers.
Footnotes
1
Both methadone preparations are 5 mg/ml and do not contain sugar, although the syrup formulation has the methadone dissolved in sorbitol, ethanol and sodium benzoate.
 
Literature
1.
go back to reference NSW Department of Health. New South Wales opioid treatment program clinical guidelines for methadone and buprenorphine treatment of opioid dependence. Sydney: NSW Department of Health; 2006. ISBN 1741870070. NSW Department of Health. New South Wales opioid treatment program clinical guidelines for methadone and buprenorphine treatment of opioid dependence. Sydney: NSW Department of Health; 2006. ISBN 1741870070.
2.
go back to reference Winstock A, Molan J, Lea T. Survey of New South Wales opioid treatment program public clinics. SWAT report 3. Sydney: NSW Department of Health & Sydney South West Area Health Service; 2007. Winstock A, Molan J, Lea T. Survey of New South Wales opioid treatment program public clinics. SWAT report 3. Sydney: NSW Department of Health & Sydney South West Area Health Service; 2007.
3.
4.
go back to reference AIHW. Alcohol and other drug treatment services in Australia 2005–06: report on the national minimum data set. Canberra: Australian Institute of Health and Welfare; 2007. AIHW. Alcohol and other drug treatment services in Australia 2005–06: report on the national minimum data set. Canberra: Australian Institute of Health and Welfare; 2007.
8.
go back to reference Sheridan J, Strang J. Role of community pharmacies in relation to HIV prevention and drug misuse: findings from the 1995 national survey in England and Wales. BMJ. 1996;313:272–4.PubMed Sheridan J, Strang J. Role of community pharmacies in relation to HIV prevention and drug misuse: findings from the 1995 national survey in England and Wales. BMJ. 1996;313:272–4.PubMed
9.
go back to reference Sheridan J, Barber N. Drug misusers’ experiences and opinions of community pharmacists and community pharmacy services. Pharm J. 1996;257:325–7. Sheridan J, Barber N. Drug misusers’ experiences and opinions of community pharmacists and community pharmacy services. Pharm J. 1996;257:325–7.
10.
go back to reference Matheson C. Illicit drug users’ views of a good and bad pharmacy service. J Soc Adm Pharm. 1998;15(2):104–16. Matheson C. Illicit drug users’ views of a good and bad pharmacy service. J Soc Adm Pharm. 1998;15(2):104–16.
13.
go back to reference Ezard N, Lintzeris N, Odgers P, Koutroulis G, Muhleisen P, Stowe A, et al. An evaluation of community methadone services in Victoria, Australia: results of a client survey. Drug Alcohol Rev. 1999;18:417–23. doi:10.1080/09595239996284.CrossRef Ezard N, Lintzeris N, Odgers P, Koutroulis G, Muhleisen P, Stowe A, et al. An evaluation of community methadone services in Victoria, Australia: results of a client survey. Drug Alcohol Rev. 1999;18:417–23. doi:10.​1080/​09595239996284.CrossRef
14.
go back to reference Madden A, Lea T, Bath N, Winstock AR. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev. 2008;(in press). Madden A, Lea T, Bath N, Winstock AR. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev. 2008;(in press).
15.
go back to reference Pharmaceutical Services Branch. Supply of methadone and buprenorphine under the New South Wales pharmacotherapy drug treatment programs: guidelines for community pharmacists. Sydney: NSW Health Department; 2004. Pharmaceutical Services Branch. Supply of methadone and buprenorphine under the New South Wales pharmacotherapy drug treatment programs: guidelines for community pharmacists. Sydney: NSW Health Department; 2004.
16.
go back to reference Treloar C, Abelson J, Cao W, Brener L, Kippax S, Schultz L, et al. Barriers and incentives to treatment for illicit drug users. Monograph series no. 53. National Drug Strategy. Canberra: Australian Government Department of Health and Ageing; 2004. ISBN 0642825556. Treloar C, Abelson J, Cao W, Brener L, Kippax S, Schultz L, et al. Barriers and incentives to treatment for illicit drug users. Monograph series no. 53. National Drug Strategy. Canberra: Australian Government Department of Health and Ageing; 2004. ISBN 0642825556.
18.
go back to reference Kehoe P, Wodak A. Patient satisfaction in a NSW public opioid pharmacotherapy clinic: measurement and responses. Technical report no. 194. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2004. ISBN 1877027855. Kehoe P, Wodak A. Patient satisfaction in a NSW public opioid pharmacotherapy clinic: measurement and responses. Technical report no. 194. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2004. ISBN 1877027855.
21.
go back to reference Winstock AR, Lea T, Molan J. New South Wales community pharmacy practice survey. SWAT report 2. Sydney: NSW Department of Health & Sydney South West Area Health Service; 2007. Winstock AR, Lea T, Molan J. New South Wales community pharmacy practice survey. SWAT report 2. Sydney: NSW Department of Health & Sydney South West Area Health Service; 2007.
23.
go back to reference Mattick RP, Digiusto E, Doran CM. OBrien S, Shanahan M, Kimber J, et al. National Evaluation of pharmacotherapies for opioid dependence (NEPOD): report of results and recommendations. Monograph series no. 52. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2001. ISBN 0642824592. Mattick RP, Digiusto E, Doran CM. OBrien S, Shanahan M, Kimber J, et al. National Evaluation of pharmacotherapies for opioid dependence (NEPOD): report of results and recommendations. Monograph series no. 52. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2001. ISBN 0642824592.
24.
go back to reference Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, et al. The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev. 2005;24:411–8. doi:10.1080/09595230500286039.PubMedCrossRef Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, et al. The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev. 2005;24:411–8. doi:10.​1080/​0959523050028603​9.PubMedCrossRef
25.
go back to reference Maddux JF, Prihoda TJ, Desmond DP. Treatment fees and retention on methadone maintenance. J Drug Issues. 1994;24:429–43. Maddux JF, Prihoda TJ, Desmond DP. Treatment fees and retention on methadone maintenance. J Drug Issues. 1994;24:429–43.
26.
go back to reference Health ACT. Increasing community based pharmacotherapy places in the act pharmacotherapy program—issues and options. Canberra: Alcohol & Other Drug Policy Unit, ACT Health; 2005. Health ACT. Increasing community based pharmacotherapy places in the act pharmacotherapy program—issues and options. Canberra: Alcohol & Other Drug Policy Unit, ACT Health; 2005.
27.
28.
go back to reference Fraser S, valentine k, Treloar C, Macmillan K. Methadone maintenance treatment in New South Wales and Victoria: takeaways, diversion and other key issues. Sydney: National Centre in HIV Social Research, University of New South Wales; 2007. Fraser S, valentine k, Treloar C, Macmillan K. Methadone maintenance treatment in New South Wales and Victoria: takeaways, diversion and other key issues. Sydney: National Centre in HIV Social Research, University of New South Wales; 2007.
32.
go back to reference Marsden J, Stewart D, Gossop M, Rolfe A, Bacciius L, Griffiths P, et al. Assessing client satisfaction with treatment for substance use problems and the development of the Treatment Perceptions Questionnaire (TPQ). Addict Res. 2000;8:455–84. doi:10.3109/16066350009005590.CrossRef Marsden J, Stewart D, Gossop M, Rolfe A, Bacciius L, Griffiths P, et al. Assessing client satisfaction with treatment for substance use problems and the development of the Treatment Perceptions Questionnaire (TPQ). Addict Res. 2000;8:455–84. doi:10.​3109/​1606635000900559​0.CrossRef
Metadata
Title
Consumer satisfaction with opioid treatment services at community pharmacies in Australia
Authors
Toby Lea
Janie Sheridan
Adam Winstock
Publication date
01-12-2008
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2008
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-008-9257-9

Other articles of this Issue 6/2008

International Journal of Clinical Pharmacy 6/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.